Delcath outlines 40 active center target and 150% HEPZATO treatment volume growth for 2025 amid CHOPIN data momentum [Seeking Alpha]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Seeking Alpha
CEO Gerard Michel highlighted the "compelling results from the investigator-sponsored CHOPIN trial" and announced the first patient dosed in the company's colorectal cancer (CRC) trial. He credited the clinical and medical affairs team for expanding Quick Insights NDRA participation led to a 13% drop in average revenue per kit and updated annual revenue guidance; gross margins, while slightly lower, are projected to remain strong at 85%-87%. The CHOPIN trial showed significant clinical benefits, expected to lessen trial competition, improve physician adoption, and support further indication trials; management is confident in positive strategic impact. Delcath plans to grow its certified treatment sites and sales regions through 2026, aiming for up to 40 sites and a 9-region sales force, focusing on referrals and increased utility at lower-volume centers. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness Wire
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]Yahoo! Finance
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Sec Filings
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- 11/13/25 - Form 4
- DCTH's page on the SEC website